Moments in Time Dataset: One Million Videos for Event Understanding.

We present the Moments in Time Dataset, a large-scale human-annotated collection of one million short videos corresponding to dynamic events unfolding within three seconds. Modeling the spatial-audio-temporal dynamics even for actions occurring in 3 second videos poses many challenges: meaningful events do not include only people, but also objects, animals, and natural phenomena; visual and auditory events can be symmetrical in time ("opening" is "closing" in reverse), and either transient or sustained. We describe the annotation process of our dataset (each video is tagged with one action or activity label among 339 different classes), analyze its scale and diversity in comparison to other large-scale video datasets for action recognition, and report results of several baseline models addressing separately, and jointly, three modalities: spatial, temporal and auditory. The Moments in Time dataset, designed to have a large coverage and diversity of events in both visual and auditory modalities, can serve as a new challenge to develop models that scale to the level of complexity and abstract reasoning that a human processes on a daily basis.

An open-label trial of granulocyte macrophage colony stimulating factor therapy for moderate symptomatic pulmonary alveolar proteinosis.

Pulmonary alveolar proteinosis (PAP) is a rare idiopathic autoimmune lung disease in adults characterized by the accumulation of lipoproteinaceous material within the alveoli of the lung. The natural history of this disease is poorly defined. Current therapy of bilateral whole-lung lavage (WLL) under general anesthesia is invasive and has its limitations. Data suggest that relative granulocyte macrophage colony stimulating factor (GM-CSF) deficiency may be involved in the pathogenesis of this disease. There have been several case series that have described clinical improvement with exogenous GM-CSF therapy in a subset of patients with PAP. We describe the results of a prospective, open-label clinical trial of daily subcutaneous GM-CSF therapy in a group of adult patients with idiopathic PAP. In this series of 25 patients, the largest reported to date, administration of GM-CSF improved oxygenation as assessed by a 10 mm Hg decrease in alveolar-arterial oxygen gradient, as well as improvement in other clinical and quality of life parameters in 12 of 25 patients (48%) with moderate symptomatic disease who completed the trial. In addition, the serum anti-GM-CSF antibody titer correlated with lung disease activity and was a predictor for responsiveness to therapy. These data indicate that subcutaneous GM-CSF therapy is a promising alternative to WLL for symptomatic patients with PAP.